Related Experiment Video

Updated: Aug 21, 2025

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.9K

The many NOs to the use of Class IC antiarrhythmics: weren't the guidelines too strict?

Dario Turturiello1, Riccardo Cappato1

  • 1IRCCS MultiMedica, via Milanese 300, Sesto San Giovanni, Milan.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|November 16, 2022
PubMed

Insights

Class IC antiarrhythmic drugs (AADs) are vital for atrial fibrillation and ventricular arrhythmias. Recent evidence suggests a favorable safety profile and efficacy in specific patient groups, challenging previous contraindications.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Class IC antiarrhythmic drugs (AADs) are essential for managing atrial fibrillation and ventricular arrhythmias.
  • Previous studies, like the Cardiac Arrhythmia Suppression Trial, led to contraindications in patients with ischemic and structural heart disease due to pro-arrhythmic effects.
  • Emerging research indicates a good safety profile and efficacy in specific patient populations previously excluded.

Purpose of the Study:

  • To review the appropriate use of Class IC AADs across diverse patient subgroups.
  • To evaluate current evidence regarding the safety and efficacy of these drugs in light of new diagnostic and therapeutic advancements.

Main Methods:

  • Literature review of recent clinical studies and trials.
  • Analysis of safety and efficacy data in various patient cohorts, including those with chronic coronary heart disease and specific structural heart diseases.
  • Evaluation of diagnostic and therapeutic tools influencing AADs' application.

Main Results:

  • Class IC AADs demonstrate a good safety profile in patients with chronic coronary heart disease without prior heart attacks or residual ischemia.
  • Excellent efficacy without pro-arrhythmic effects is observed in patients with structural heart diseases like arrhythmogenic right ventricular cardiomyopathy (ARVC) and tachycardiomyopathy.
  • The review highlights a shift in understanding the risk-benefit ratio of Class IC AADs in selected patient groups.

Conclusions:

  • Class IC AADs can be safely and effectively used in specific patient subgroups, including those with certain types of structural heart disease and chronic coronary heart disease.
  • Re-evaluation of contraindications based on recent evidence is warranted for optimal patient management.
  • The appropriate selection of patients and utilization of modern tools are key to maximizing the benefits of Class IC AADs while minimizing risks.

Keywords:
Class IC antiarrhytmic drugsrestoration of sinus rhythm

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.2K

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
818
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
939
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
29
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
680